Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B)

Lung Cancer. 2026 May 12;217:109456. doi: 10.1016/j.lungcan.2026.109456. Online ahead of print.ABSTRACTBACKGROUND: Optimal management of advanced thymoma remains uncertain. We compared the efficacy of first-line platinum-anthracycline chemotherapy with other platinum-based regimens in a large Japane

G Go Saito

Longitudinal associations of cumulative and repeated-measure patterns of insulin resistance surrogate indices with biological age acceleration and incident cardiovascular disease across cardiovascular-kidney-metabolic syndrome stages 0-3: evidence from CHARLS 2011-2020

Cardiovasc Diabetol. 2026 May 16. doi: 10.1186/s12933-026-03206-z. Online ahead of print.ABSTRACTBACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3 represent a critical window for preventing progression to overt cardiovascular disease (CVD). Insulin resistance (IR) is central to C

S Shu-Shu Han

Early postoperative treprostinil in for severe pulmonary arterial hypertension in a high-risk pediatric patient with complete atrioventricular septal defect: a case report

BMC Cardiovasc Disord. 2026 May 16. doi: 10.1186/s12872-026-05954-y. Online ahead of print.ABSTRACTBACKGROUND: Perioperative management of pediatric patients with congenital heart disease (CHD) and severe pulmonary arterial hypertension (PAH) remains challenging because of limited evidence-based gui

S Sha Zhao

Diagnostic value of miR-148b-3p in left ventricular hypertrophy patients with hypertension

BMC Cardiovasc Disord. 2026 May 16. doi: 10.1186/s12872-026-05939-x. Online ahead of print.ABSTRACTBACKGROUND: To explore the expression characteristics, diagnostic value, and regulatory role of miR-148b-3p in hypertensive patients with left ventricular hypertrophy (LVH), providing preliminary evide

K Kai Xie

Predictors of metabolic syndrome among type II diabetic patients visiting public hospitals in Sidama Region, Ethiopia: unmatched case control study

BMC Cardiovasc Disord. 2026 May 16. doi: 10.1186/s12872-026-05982-8. Online ahead of print.ABSTRACTINTRODUCTION: Metabolic syndrome (MetS) is a series of health conditions, including insulin resistance, abdominal obesity, hypertension, and dyslipidemia. In diabetic patients, MetS elevates the risks

B Bereket Sisay Gebremichael

Endovascular thrombectomy versus best medical therapy for acute vertebrobasilar artery occlusion in patients with low NIHSS scores: a meta-analysis

Ann Med. 2026 Dec;58(1):2673631. doi: 10.1080/07853890.2026.2673631. Epub 2026 May 16.ABSTRACTOBJECTIVE: The efficacy of endovascular thrombectomy (EVT) for acute vertebrobasilar artery occlusion (VBAO) presenting with mild symptoms (National Institutes of Health Stroke Scale [NIHSS] score ≤10) rema

Y Yaqin Qin

Coronary Artery Disease in Masters Athletes: A Systematic Review

Sports Med. 2026 May 16. doi: 10.1007/s40279-026-02429-0. Online ahead of print.ABSTRACTBACKGROUND: Despite undertaking large volumes of structured exercise training, evidence suggests that masters athletes (MAs) remain susceptible to coronary artery disease (CAD). This review evaluated the prevalen

S Shaqira Gill

Impact of age on clinical outcomes after endovascular therapy for large ischemic stroke

J Neurol. 2026 May 16;273(6):317. doi: 10.1007/s00415-026-13844-8.ABSTRACTBACKGROUND: The impact of age on outcomes in patients with large ischemic stroke [defined as Alberta Stroke Program Early Computed Tomography Score (ASPECTS) ≤ 5] remains unclear. This study aimed to explore the effect of age

H Haoxuan Zhu

Prognostic value of pretest probability of heart failure with preserved ejection fraction in patients with coronary artery disease: an insight from the CLIDAS-PCI database

Cardiovasc Interv Ther. 2026 May 16. doi: 10.1007/s12928-026-01286-y. Online ahead of print.ABSTRACTCoronary artery disease (CAD) is a major risk factor for the development of heart failure (HF) with preserved ejection fraction (HFpEF) and is associated with increased mortality. However, an optimal

T Tomoaki Nishikawa

Kullback-Leibler divergence in feature selection: a methodology for improved detection of heart valve disorders

Phys Eng Sci Med. 2026 May 16. doi: 10.1007/s13246-026-01737-z. Online ahead of print.ABSTRACTDimensionality reduction is crucial for the effective management of high-dimensional datasets, particularly in the healthcare industry. Feature selection identifies the most relevant attributes, reducing co

V V H Preetha

Drug-coated balloon angioplasty in coronary artery disease: state of the art review

NPJ Cardiovasc Health. 2026 May 16. doi: 10.1038/s44325-026-00132-7. Online ahead of print.ABSTRACTDrug-coated balloons (DCBs) provide a "leave-nothing-behind" revascularization strategy, delivering antiproliferative therapy without permanent implants. This review presents evidence on DCB performanc

P Panagiotis Theofilis

Tolerability and efficacy of full-body head-up tilt sleeping in Parkinson's disease and multiple system atrophy

NPJ Parkinsons Dis. 2026 May 16. doi: 10.1038/s41531-026-01359-y. Online ahead of print.ABSTRACTOrthostatic hypotension (OH) and the co-existence with supine hypertension (SH) are debilitating consequences of autonomic failure in Parkinson's disease (PD) and multiple system atrophy (MSA). Head-up ti

A Amber H van der Stam

An era of precision: Emerging, research, and adjunct radiotracers for nuclear imaging of cardiac amyloidosis

J Nucl Cardiol. 2026 May;59S:102726. doi: 10.1016/j.nuclcard.2026.102726. Epub 2026 May 15.ABSTRACTCardiac amyloidosis (CA) has rapidly transitioned from an underrecognized cause of heart failure to a treatable protein-misfolding cardiomyopathy, driven by advances in transthyretin (TTR) stabilizatio

J Jonathan S Wall

Multimodality imaging in cardiac amyloidosis: When and how to combine nuclear techniques with echocardiography and cardiac magnetic resonance imaging

J Nucl Cardiol. 2026 May;59S:102728. doi: 10.1016/j.nuclcard.2026.102728. Epub 2026 May 15.ABSTRACTEchocardiography and cardiac magnetic resonance (CMR) can demonstrate features of myocardial infiltration in cardiac amyloidosis, but cannot independently establish a definitive diagnosis or determine

D Dominik C Benz

Cardiac amyloid radionuclide imaging: Global perspective and future priorities

J Nucl Cardiol. 2026 May;59S:102725. doi: 10.1016/j.nuclcard.2026.102725. Epub 2026 May 15.ABSTRACTTransthyretin amyloid cardiomyopathy (ATTR-CM) has transitioned from a rare, untreatable condition to a prevalent and treatable cause of heart failure, driven by advances in disease-modifying therapies

F Firas Al Badarin

Quantitative cardiac amyloid radionuclide imaging

J Nucl Cardiol. 2026 May;59S:102724. doi: 10.1016/j.nuclcard.2026.102724. Epub 2026 May 15.ABSTRACTCardiac amyloid radionuclide imaging (CARI) with single-photon emission computed tomography (SPECT) bone-avid tracers plays a key role in the noninvasive detection of transthyretin cardiac amyloidosis

R Robert Jh Miller

Cardiac amyloidosis: Disease overview and novel pathophysiologic insights

J Nucl Cardiol. 2026 May;59S:102723. doi: 10.1016/j.nuclcard.2026.102723. Epub 2026 May 15.ABSTRACTCardiac amyloidosis (CA) has transitioned from a rare, frequently fatal disease to an increasingly recognized cause of heart failure, driven by heightened awareness, noninvasive diagnostic strategies,

G Gregorio Tersalvi

Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes

Clin Liver Dis. 2026 May;30(2):381-390. doi: 10.1016/j.cld.2026.01.003. Epub 2026 Mar 23.ABSTRACTMetabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease, is increasingly prevalent and closely linked to obesity and type 2 diabetes (T2D). These metab

S Sonal Kumar

Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases

Clin Liver Dis. 2026 May;30(2):301-322. doi: 10.1016/j.cld.2025.12.003. Epub 2026 Feb 27.ABSTRACTMetabolic dysfunction-associated steatotic liver disease (MASLD), recently redefined to emphasize its metabolic underpinnings, is emerging as a systemic disorder that extends well beyond the liver. Accum

A Amalia Gastaldelli

Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases: Diabetes, Prediabetes, and Obesity

Clin Liver Dis. 2026 May;30(2):271-288. doi: 10.1016/j.cld.2025.12.001. Epub 2026 Mar 9.ABSTRACTMetabolic dysfunction-associated steatohepatitis is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation, with the burden rising rapidly in people with type 2 diabetes, predia

L Leonidas Diamantopoulos

Sudden cardiac death and major arrhythmic events in patients with Fabry disease: risk stratification in the FHFc multicenter study

Heart Rhythm. 2026 May 15:S1547-5271(26)02388-X. doi: 10.1016/j.hrthm.2026.05.021. Online ahead of print.ABSTRACTBACKGROUND: Fabry disease (FD) is a rare X-linked genetic disorder due to alpha-galactosidase deficiency. Cardiovascular complications, including ventricular arrhythmias and conduction ab

Y Yassine Temmar

Ultra-Processed Foods and Cardiovascular Health Risks; a position review of current evidence, guidelines and statements

Hellenic J Cardiol. 2026 May 15:S1109-9666(26)00088-6. doi: 10.1016/j.hjc.2026.05.002. Online ahead of print.ABSTRACTUltra-processed foods (UPFs) are industrial products formulated largely from extracted or refined food constituents, such as sugars, starches, oils, and protein isolates, and typicall

E Emmanuella Magriplis

Globotriaosylceramide (Gb3) implications in cardiovascular disease for its mechanistic insights, food chemistry aspects and clinical significance - A review

Int J Biol Macromol. 2026 May 15:152557. doi: 10.1016/j.ijbiomac.2026.152557. Online ahead of print.ABSTRACTCardiovascular disease (CVD) is a major non-communicable disease that can be influenced by the accumulation of Globotriaosylceramide (Gb3), a glycosphingolipid associated with circulating lipo

V Vaishali Roy

Investigating the comparability of wearable accelerometer methods in the association between physical activity and cardiovascular disease: a cohort study using UK Biobank

Prev Med. 2026 May 15:108603. doi: 10.1016/j.ypmed.2026.108603. Online ahead of print.ABSTRACTOBJECTIVE: The selection of accelerometer processing methods may influence the shape of the dose-response association between wearable-measured physical activity and health outcomes. We aimed to compare the

Y Yacine Lapointe